News & Updates

Show Multimedia Only

OSA linked to thromboembolic event risk among women with PCOS

Women with polycystic ovarian syndrome (PCOS) may have an increased risk of thromboembolic events in the presence of obstructive sleep apnoea (OSA), according to a retrospective study.

OSA linked to thromboembolic event risk among women with PCOS

a day ago

Improved cardiometabolic outcomes seen after surgical remission of endogenous hypercortisolism

a day ago

Cardiometabolic comorbidities have shown improvements following surgery in patients with Cushing syndrome (CS) and those with mild autonomous cortisol secretion (MACS), reports a study.

Improved cardiometabolic outcomes seen after surgical remission of endogenous hypercortisolism

a day ago

GLP‐1RA offers cardiovascular, survival benefits in high-risk population

a day ago

The use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among adults with obesity and concomitant autoimmune diseases appears to lower the incidence of thromboembolic events, emergency department visits, and mortality, according to a study.

GLP‐1RA offers cardiovascular, survival benefits in high-risk population

a day ago

Orforglipron superior to dapagliflozin in metformin-resistant T2D

19 Jun 2026 by

A recent study comparing dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, with orforglipron, an oral nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist (RA), has found superior glycaemic control and weight loss with the latter.

Orforglipron superior to dapagliflozin in metformin-resistant T2D

19 Jun 2026

Mazdutide cuts weight in adults with obesity, T2D

19 Jun 2026 by

The use of mazdutide among adults with obesity results in a clinically significant weight reduction and improvements in cardiometabolic risk factors, with an acceptable safety profile, as shown in the phase 3 GLORY-2 trial presented at ADA 2026.

Mazdutide cuts weight in adults with obesity, T2D

19 Jun 2026

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

19 Jun 2026 by

In a post hoc analysis of the phase III MAESTRO-NASH trial presented at ADA 2026, systemic thyroid function remained stable with resmetirom, supporting its extrahepatic safety in individuals with metabolic dysfunction-associated steatohepatitis (MASH).

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

19 Jun 2026

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

18 Jun 2026 by

For individuals with type 2 diabetes (T2D) that is inadequately controlled by diet and exercise alone, once-weekly administration of the triple hormone receptor agonist retatrutide helps improve glycaemic control, and this benefit is accompanied by substantial weight reduction, as shown in the phase III TRANSCEND-T2D-1 study.

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

18 Jun 2026

Add-on orforglipron improves outcomes in T2D patients on insulin glargine

17 Jun 2026 by

Daily treatment with oral orforglipron, when added to titrated insulin glargine, has been shown to be beneficial in individuals with inadequately controlled type 2 diabetes (T2D) in the phase 3 ACHIEVE-5 trial.

Add-on orforglipron improves outcomes in T2D patients on insulin glargine

17 Jun 2026

Tirzepatide superior to ICC in metformin-resistant T2D

17 Jun 2026

Treatment with tirzepatide yields robust reductions in HbA1c, weight, and waist circumference in patients with early type 2 diabetes (T2D) uncontrolled with metformin, reports a study.

Tirzepatide superior to ICC in metformin-resistant T2D

17 Jun 2026

Weight, income status modify impact of extreme temperature events on daily step counts

14 Jun 2026

Individuals with low income or high BMI appear to be more vulnerable to heatwaves, while those with low income or normal BMI tend to have greater sensitivity during cold spells, both of which contribute to fewer daily step counts, suggests a study.

Weight, income status modify impact of extreme temperature events on daily step counts

14 Jun 2026

News & Updates

Showing Endocrinology articles

Showing

Specialty:

OSA linked to thromboembolic event risk among women with PCOS

OSA linked to thromboembolic event risk among women with PCOS

Improved cardiometabolic outcomes seen after surgical remission of endogenous hypercortisolism

Improved cardiometabolic outcomes seen after surgical remission of endogenous hypercortisolism

GLP‐1RA offers cardiovascular, survival benefits in high-risk population

GLP‐1RA offers cardiovascular, survival benefits in high-risk population

Orforglipron superior to dapagliflozin in metformin-resistant T2D

Orforglipron superior to dapagliflozin in metformin-resistant T2D

Mazdutide cuts weight in adults with obesity, T2D

Mazdutide cuts weight in adults with obesity, T2D

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

Add-on orforglipron improves outcomes in T2D patients on insulin glargine

Add-on orforglipron improves outcomes in T2D patients on insulin glargine

Tirzepatide superior to ICC in metformin-resistant T2D

Tirzepatide superior to ICC in metformin-resistant T2D

Weight, income status modify impact of extreme temperature events on daily step counts

Weight, income status modify impact of extreme temperature events on daily step counts